November 14, 2024 | 2 months ago

Numerous pharmaceutical projects under way: Saidal, powerhouse of local industry

As part of its drive to improve health safety, Algeria has invested heavily in developing a high-performance pharmaceutical industry, relying in particular on the state-owned Saidal group. Indeed, the group is carrying out various projects, in partnership with world leaders, to produce the new drugs required to treat diseases like cancer, heart disease, diabetes and others.

Algeria Invest
Legal Notices | Terms of Services
news-detail

The Saidal Group is a key player in Algeria's pharmaceutical industry aiming for national self-sufficiency while positioning itself as a regional leader. It meets 70% of the national demand for medicines and aims to reach 100% within five years. Saidal also plans to export two-thirds of its production, targeting markets in Europe, India, and Africa.


Strategic axes:

 

-Increase local production:
-Launch 100 new medicines.
-Reduce cancer drug imports by $300 million with 27 oncology drugs by 2025.

 

Raw material production:
Launch 9 active pharmaceutical ingredient manufacturing projects, including:

     - Diabetes and cardiovascular medicines in Batna.
- Paracetamol and aspirin in Batna.
-Cancer drugs in Sétif.
-Antibiotics in Médéa.

 

Innovation and export:


-Creation of a cell therapy laboratory and a specialised hospital.
-Partnership with the Karolinska Institute for the treatment of resistant cancers.
-Development of vaccines with a world leader, including flu and paediatric vaccines.
-Doubling exports, with medicines already registered in several African countries.

 

New factories:

-Two factories in Mostaganem for ophthalmic and animal health products, potentially reducing imports by over $200 million.

 

Saidal aims to become a leading pharmaceutical company in Africa and the Middle East, contributing to import reduction and national economic development.

November 14, 2024 | algeria-logo